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Abstract
It is not clear if patients with heterogeneous intermediate resistance to vancomycin (hVISA) infectious endocarditis (IE) differ from
methicillin-resistant S. aureus (MRSA) IE patients. All cases of hVISA and MRSA IE diagnosed at the Sheba Medical Centre from 2003 to
2010 were included. Isolates were screened prospectively for hVISA. Medical records were reviewed. The t-test, chi-square test, Fisher
exact test and Kaplan Meier analysis were used. Fourteen hVISA IE and 32 MRSA IE were identiﬁed. The mean age was 76 years, mean
Charlson score was 4.5 and 24% of patients had prosthetic valves. Pacemakers and implantable cardioverter-deﬁbrillators (P/ICDs) were
more common in the hVISA group (50% vs. 22%, p 0.05). P/ICDs IE occurred in 29% of hVISA patients vs. 6.3% of MRSA patients (p 0.06).
hVISA patients had more positive blood cultures (eight vs. ﬁve, p 0.007) and a trend toward longer bacteraemia (15 vs. 7.5 days, p 0.08).
Vancomycin minimal inhibitory concentrations (MICs) were similar in the two groups (1.5 lg/mL vs. 1.1 lg/mL, p 0.11). The MIC to
daptomycin was higher in hVISA (0.75 lg/mL vs. 0.32 lg/mL, p 0.049). MRSA patients received vancomycin. hVISA patients were switched
to other antibiotics. Cardiac surgery and/or P/ICD extraction was performed more commonly in hVISA patients (50% vs. 16%, p 0.027).
Mortality was high in both groups (57–66%). The median time to death was 39 days in the hVISA group and 19 days in the MRSA group (p
0.3). hVISA IE is associated with P/ICDs. Both hVISA and MRSA are associated with high mortality. Low rates of surgical intervention and
P/ICD extraction reﬂect the high co-morbidity of patients. Caution should be employed in the empirical use of daptomycin in hVISA
patients.
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Background
In the past decade Staphylococcus aureus has become the most
prevalent organism causing infectious endocarditis (IE). This is
related to the increased prevalence of heart valve transplan-
tation, increased number of patients undergoing pacemaker
and deﬁbrillator transplantation, and the increase in the
numbers of healthcare-related procedures, in particular inser-
tion of various endovascular catheters [1,2].
The percentage of IE due to methicillin-resistant S. aureus
(MRSA) depends on local epidemiology. In recent publications,
in developed countries, between 20% and 30% of all S. aureus
IE were attributed to MRSA. Healthcare-associated IE, which
commonly is attributed to MRSA, was associated with high
mortality rates [3].
Staphylococcus aureus with heterogeneous intermediate
resistance to vancomycin (hVISA) is an emerging disease.
The mechanism of resistance of hVISA and VISA isolates is not
known. Phenotypically these isolates have a thick peptidogly-
can layer that entraps vancomycin molecules and thus prevents
vancomycin from destroying the cell wall. Although several
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genes have been associated with the hVISA phenotype, the
speciﬁc genetic mechanism that causes this type of resistance is
not known [4].
Patients with hVISA blood stream infections have signiﬁ-
cantly longer bacteraemia compared with patients with blood
stream infections due to MRSA. They also have higher rates of
IE compared with MRSA bacteraemic patients. Infection-attrib-
utable mortality is high in both groups of patients, in the range
of 40% [5,6].
Data regarding the presentation of hVISA IE and the unique
features of hVISA IE compared with MRSA IE are limited [7].
The aim of this study was to assess the prevalence, clinical
course and outcomes of hVISA IE and to compare these
patients with patients with MRSA IE in a tertiary care centre in
Israel. Sheba Medical Centre is a tertiary care centre with 1800
beds. The Leviev Heart Centre comprises one of the largest
interdisciplinary heart centres in Israel. It includes a cardio-
thoracic surgery department and a large cardiac department
with intensive care beds.
Methods
Case and control patients
All cases of hVISA IE diagnosed at the Sheba Medical Centre
(Tel Hashomer, Israel) from 2003 through to 2010 were
included. The control group consisted of all patients with MRSA
IE during the same time period. IE was diagnosed according to
the modiﬁed Duke criteria [8]. The study was approved by the
Sheba Medical Centre institutional review board.
Laboratory methods
Resistance to methicillin was identiﬁed by the cefoxitin disk
diffusion method [9]. All isolates included in the study were
assessed prospectively for the presence of hVISA resistance by
the Etest macromethod, as previously described [10]. The
macromethod was performed on fresh inoculated samples (18
to 24 h) because reversion of resistance after laboratory
manipulation had been reported [11]. In brief, strains were
grown for 18–24 h on blood agar plates. Randomly selected
isolated colonies were inoculated into brain-heart infusion
(BHI) broth. One hundred microlitres of 2.0 McFarland
suspensions were drawn onto BHI agar plates. Etest strips
(AB bioMerieux, Lyon, France) for vancomycin and teicoplanin
were applied on the same plate, which was subsequently
incubated at 35°C for 48 h. Strains were considered hVISA if
readings were ≥8 lg/mL for both vancomycin and teicoplanin,
or ≥12 lg/mL for teicoplanin alone. Laboratory workers were
blinded to patients’ clinical characteristics. In a previous study
[12] we validated the presence of hVISA identiﬁed by the Etest
macromethod vs. the modiﬁed population analysis method
[13]. In all isolates tested (n = 20) the hVISA phenotype was
conﬁrmed. Hence, speciﬁcity was 100% and sensitivity was not
assessed.
Minimal inhibitory concentrations (MICs) and minimal
bactericidal concentrations (MBCs) of vancomycin were
assessed prospectively in all isolates using the broth micro-
dilution method according to the Clinical and Laboratory
Standards Institute (CLSI) guidelines [14,15], with S. aureus
ATCC 29213 as a control strain. Tolerance was deﬁned as
MBC/MIC ratio of ≥16 [15,16]. Antibiotic susceptibility testing
to all other antibiotics was performed by disk diffusion or Etest
according to CLSI guidelines [9] and the manufacturers’
instructions.
Clinical data
The medical records of all patients were reviewed and data
were retrieved by a questionnaire that summarized demo-
graphic and clinical characteristics as well as functional
capacity. Co-morbidity before the bacteraemia was assessed
by the Charlson [17] co-morbidity index, and was demon-
strated to be a good predictor of mortality in patients with
S. aureus bacteraemia [18]. Additional variables related to
co-morbidity were also recorded, including presence of
prosthetic heart valves, pacemakers and implantable cardio-
verter-deﬁbrillators (P/ICDs). Healthcare-associated IE was
deﬁned as: IE developing in a patient hospitalized >48 h prior
to the onset of signs/symptoms consistent with IE; IE
developing <48 h after hospitalization in patients receiving
home-based intravenous treatment, hemodialysis or intrave-
nous chemotherapy <30 days before the onset of IE; or
patients hospitalized in an acute care facility <90 days before
the onset of IE [19]. Data were also collected on antibiotic
treatment (the standard vancomycin regimen at the Sheba
Medical Centre is 1 g twice daily), trough vancomycin levels,
echocardiography results (echocardiography is performed
routinely for all patients with S. aureus bacteraemia), presence
of endocarditis according to the modiﬁed Duke criteria [8],
duration of bacteraemia, frequency of blood collection for
culture, and mortality.
Indications for surgery and or P/ICD extraction in our
institution are a follows.
1. For patients with prosthetic valves or a P/ICD:
i. persistence of S. aureus bacteraemia >48 h
ii. presence of vegetations or abscess regardless of the
length of bacteraemia
iii. pulmonary oedema
2. For patients with native valves that do not have an implanted
P/ICD:
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i. persistence of S. aureus bacteraemia >7 days
ii. cardiac abscess formation demonstrated by trans eso-
phageal echocardiography regardless of the length of
bacteraemia
iii. left-sided vegetations larger than 1 cm demonstrated on
echocardiography
iv. pulmonary oedema
Statistical analysis
All information retrieved from patients’ charts and the
laboratory was abstracted in a tabular manner, using an Excel
datasheet. Statistical analysis was performed using SPSS
software. The Student t-test, the Pearson chi-square test and
the Fisher exact test were used for comparisons, as appro-
priate, with the level of signiﬁcance set at a p value of <0.05.
Kaplan–Meier analysis was used to compute survival in both
groups and the log rank test was used to assess signiﬁcance
between groups. Patients were censored at 360 days.
Results
During an 8-year period we identiﬁed 14 cases of hVISA IE
(30%) and 32 cases of MRSA IE (70%). Patients’ characteristics
are presented in Table 1. The mean age was 74 years in the
hVISA group and 77 years in the MRSA group. Between 60%
and 70% were male. Both groups had a high co-morbidity
index as reﬂected by the Charlson score (4.4 (SD 3.4) and 4.6
(SD 2.7), respectfully). About 40% of patients in both groups
had diabetes and chronic renal failure.
When reviewing the cardiovascular co-morbidities there
was no difference in the rate of prosthetic valves between
hVISA and MRSA patients (three (21.4%) and eight (25.0),
respectfully, p 0.8) but hVISA patients had signiﬁcantly more P/
ICDs (seven (50%) and seven (21.9%), respectfully, p 0.05).
The rate of deﬁnite IE, native valve IE and prosthetic valve IE
was similar in both groups but P/ICD IE tended to be more
common in the hVISA group (four (28.6%) and two (6.3%),
respectfully, p 0.06). All hVISA cases and all but two MRSA
cases were nosocomial infections.
Antibiotic susceptibilities of the isolates are presented in
Table 2. Vancomycin MICs were not statistically different
between the two groups (1.5 lg/mL (SD 0.59) vs. 1.1 lg/mL
(SD 0.5), respectfully, p 0.11) but there was a trend towards
higher rates of tolerance in the hVISA group (six (54.5%) vs.
two (15.4%), respectfully, p 0.08). All patients were na€ıve to
daptomycin, linezolid and tigecycline. MIC to daptomycin was
higher in hVISA isolates (0.75 lg/mL (SD 0.72) vs. 0.32 lg/mL
(SD 0.16), respectfully, p 0.049). Two cases (14%) demon-
strated resistance to daptomycin in the hVISA group, and none
were resistant in the MRSA group. There was no difference in
the MICs to linezolid between the groups.
Clinical course and outcomes differed between hVISA and
MRSA patients (Table 3).
Shock was present in ﬁve (35.7%) hVISA patients and seven
(21.9%) MRSA patients. These patients also developed overt
congestive heart failure. Signiﬁcantly more blood cultures were
taken in the hVISA group (eight (SD 4.7) vs. ﬁve (SD 2.4),
respectfully, p 0.007), and there was a trend towards a more
prolonged bacteraemia in the hVISA group (median length of
TABLE 1. Patients’ characteristics
hVISA IE, n = 14 MRSA IE, n = 32 p value
Socio-demographic details
Age (years) (SD) 74.2 (12.8) 77.4 (20.1) 0.6
Males (%) 10 (71.4) 20 (62.5) 0.6
General medical history
Charlson score (SD) 4.4 (3.4) 4.6 (2.7) 0.8
Diabetes (%) 6 (42.9) 11 (34.4) 0.6
Chronic renal failure 5 (35.7) 14 (43.8) 0.6
Cardiac medical history
Prosthetic valves (%) 3 (21.4) 8 (25.0) 0.8
P/ICD (%) 7 (50.0) 7 (21.9) 0.05
Deﬁnition and site of IE
Deﬁnite IE (%) 10 (71.4) 23 (71.9) 0.98
Native valve IE (%) 4 (28.6) 17 (53.1) 0.12
Prosthetic valve IE (%) 3 (21.4) 8 (25.0) 0.8
P/ICD IE (%) 4 (28.6) 2 (6.3) 0.06
IVDU (%) 0 0 –
TABLE 2. Antibiotic susceptibility of Staphylococcus aureus
isolates
hVISA IE,
n = 14
MRSA IE,
n = 32
p
value
Vancomycin MIC lg/mL (SD) 1.5 (0.59) 1.1 (0.50) 0.11
Vancomycin tolerance (%) 6 (54.5) 2 (15.4) 0.08
Daptomycin Etest MIC lg/mL
(SD)
0.75 (0.72) 0.32 (0.16) 0.049
Linezolid Etest lg/mL (SD) 0.55 (0.27) 0.83 (0.62) 0.4
Tigecycline Etest lg/mL (SD) 0.17 (0.07) 0.26 (0.21) 0.5
TABLE 3. Clinical course and outcome
hVISA IE,
n = 14
MRSA IE,
n = 32
p
value
Number of blood cultures (SD) 8 (4.7) 5 (2.4) 0.007
Medical length of bacteraemia (days) 15 7.5 0.08
Embolic phenomena (%) 4 (28.6) 7 (21.9) 0.6
CNS bleeding/new neurological deﬁcits
(%)
0 7 (21.9) 0.08
Cardiac surgery and/or P/ICD extraction
(%)
7 (50.0) 5 (15.6) 0.027
Antibiotic treatment
Vancomycin 14 (100.0) 32 (100.0)
Daptomycin 5 (35.7) 0
Linezolid 1 (7.1) 0
Trimethoprim/sulphamethoxazole 2 (14.3) 1 (3.1)
Gentamicin 3 (21.5) 5 (15.6)
Rifampicin 9 (64.3) 8 (25.0)
Fusidic acid 2 (14.3) 0
Mortality (%) 8 (57.1) 21 (65.6) 0.6
Median time from ﬁrst positive blood
culture to death (days)
39 19 0.3
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bacteraemia 15 days vs. 7.5 days in the MRSA group, p 0.08).
CNS involvement (bleeding/new neurological deﬁcits) tended
to be more common in MRSA patients (0 vs. 7 (21.9%), p 0.08)
but there was no difference in the number of embolic events
diagnosed between the groups. On transthoracic echocardi-
ography examination three (21.4%) hVISA patients and four
(12.5%) MRSA patients had cardiac abscesses. Cardiac surgery
or P/ICD extraction was indicated in 11 (78.6%) hVISA IE
patients and in 25 (78.1%) MRSA patients. De facto these
procedures were performed more commonly in hVISA
patients compared with MRSA patients (seven (50.0%) vs. ﬁve
(15.6%), respectfully, p 0.027). When looking at left-sided IE
(omitting patients with P/ICD right-sided IE), cardiac surgery
was performed in two (14.3%) hVISA patients and in three
(9.4%) MRSA patients.
All MRSA patients were treated with vancomycin. One
patient was switched to trimethoprim/sulphamethoxazole. Five
patients (15.6%) received adjunctive treatment with gentamicin
and eight patients (25%) received adjunctive treatment with
rifampicin. None were treated with daptomycin or linezolid.
One patient was switched to SMX-TMP. All hVISA patients
were initially treated with vancomycin. Three patients (21.5%)
received adjunctive treatment with gentamicin and nine
patients (64.3%) received adjunctive treatment with rifampicin.
Five patients (35.7%) were switched to daptomycin, one
patient was switched to linezolid, six patients (42.9%) were
switched to SMX-TMP and two patients (14.3%) were
switched to fusidic acid. Changes in antibiotic treatment were
carried out according to susceptibility tests and the physicians’
discretion (Table 3). Treatment with daptomycin or SMX-TMP
was signiﬁcantly more common in hVISA patients (p 0.02 and p
0.03, respectfully).
Mortality was high in both groups (57.1–65.6%). Median
time from ﬁrst positive blood culture to death was 39 days in
hVISA patients and 19 days in MRSA patients, p 0.3 (Fig. 1). All
deaths were attributed to infectious complications. There
were no signiﬁcant differences in mortality between patients
who received daptomycin or other antibiotics.
Discussion
In our report, over an 8-year period, 30% of MRSA IE cases
were due to the hVISA phenotype. Since 2003 all MRSA blood
stream isolates in our institution were assessed prospectively
for the presence of the hVISA phenotype using the Etest
Macromethod. In this respect we can provide unique clinical
data reﬂecting a ‘real world’ situation. Most laboratories
worldwide do not assess routinely for the presence of this
type of resistance and therefore a search for hVISA isolates is
FIG. 1. Kaplan–Meier plots for survival in hVISA and MRSA patients. Kaplan–Meier plots were computed to plot survival in hVISA and MRSA
patients. Median time to death was 39 and 19 days in hVISA and MRSA groups, respectively. Signiﬁcance by the log rank test was p 0.3.
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carried out either in a research set-up or upon speciﬁc
demand. This approach inherently introduces signiﬁcant bias,
usually reﬂecting severe and complicated cases. To understand
the clinical signiﬁcance of hVISA resistance it is important to
assess all patients with MRSA isolates, as we have done. As the
identiﬁcation of hVISA was carried out as part of a routine
busy clinical service, we chose to use the Etest Macromethod
for identifying resistance. We have previously validated this
method compared with population analysis [13] and therefore
we feel conﬁdent that the Etest Macromethod in our hands
identiﬁed most cases of hVISA resistance.
We have previously published a large clinical series dem-
onstrating a high prevalence of IE among hVISA bacteraemic
patients compared with MRSA bacteraemic patients [6]. We
now proceeded to assess whether the hVISA phenotype
affects the clinical course and outcome of IE compared with
MRSA IE. Patients in both groups were elderly with much
co-morbidity and in both groups about 20% had prosthetic
valves. hVISA patients had a signiﬁcantly higher rate of P/ICDs,
and hence right-sided IE was more common in this group.
Right-sided IE is considered a milder disease than left-sided IE.
Despite this, length of bacteraemia, which may be considered
as a marker of the bacterial inoculum and the severity of IE,
tended to be longer in hVISA patients (median length of
bacteraemia 15 days vs. 7.5 days in the MRSA group, p 0.08).
In the only series of hVISA IE published by Bae [7], patients
with hVISA IE were older than MRSA patients and none were
drug users. Persistent bacteraemia deﬁned as positive blood
cultures after 3 days of antibiotic treatment was also more
common among hVISA IE patients. In that series, most patients
had native valve IE, which is not typical of MRSA isolates. In our
series most cases were related to prosthetic valves or P/ICDs.
In particular, hVISA IE was related to P/ICDs in 40% of cases.
In contrast to Bae’s report, where CNS involvement was
similar in hVISA and MRSA patients [7], CNS involvement in
the current series tended to be more common in MRSA
patients (0 vs. 7 (21.9%), p 0.08) but there was no difference in
the number of embolic events diagnosed between the groups.
This probably reﬂects a higher rate of left-sided endocarditis in
the MRSA patients. Our data suggest that hVISA IE patients
were managed differently to MRSA IE patients. Cardiac surgery
and/or P/ICD extraction was performed more commonly in
hVISA patients (seven (50.0%) vs. ﬁve (15.6%), respectfully, p
0.027). As surgery is considered an important therapeutic
approach in patients with prosthetic valves or devices,
particularly in the context of MRSA IE, these results are
surprising. The reason for this conservative approach was the
poor general condition of many patients included in this series,
as reﬂected by age and much co-morbidity, thus posing a high
surgical risk. It is also possible that in the hVISA group
infectious disease consultation was more common, also
affecting the clinical approach to these patients. The high
mortality rate, approaching 65%, calls for reconsideration of
this conservative clinical approach as recent studies have
demonstrated a survival beneﬁt in patients undergoing early
surgery [20–22].
Emerging resistance to daptomycin is of concern in hVISA
isolates. In a study assessing the prevalence of hVISA in
S. aureus in the United States, 9% of hVISA isolates were
resistant to daptomycin [23]. In another study from Australia,
26% of isolates na€ıve to daptomycin demonstrated resistance
by Etest [24]. Resistance is related to an increased cell-wall
turnover, and an increased positive cell-wall charge responsi-
ble for a repulsion mechanism towards vancomycin and
daptomycin [25]. hVISA isolates in our series had a signiﬁcantly
higher MIC to daptomycin compared with MRSA isolates and
two cases were resistant to daptomycin. It is important to
realize that this resistance occurred in patients na€ıve to
daptomycin. Also of note, the use of daptomycin in our
hospital is very rare, as this drug is reserved only for patients
with severe hVISA infections and it is not given currently in our
facility to patients with vancomycin-resistant enterococci
infections. Therefore the increase in daptomycin MIC reﬂects
a spontaneous mechanism related perhaps to vancomycin
pressure. These data also demonstrate the importance of
daptomycin susceptibility testing prior to treatment in hVISA
cases. The small sample size of this series does not allow us to
recommend a speciﬁc antibiotic regimen for hVISA patients.
Our cumulative experience in these patients, whether with
endocarditis or bacteraemia [5,6], suggests that an early shift
from vancomycin treatment to other antibiotics beneﬁts
patients. We have not encountered yet in our institution
resistance to linezolid, so currently this is our preferred
regimen for hVISA patients. Further study is needed to validate
our opinion.
This study has several caveats. The number of hVISA cases
was relatively small, and clinical data were retrieved retro-
spectively and therefore may be biased. Also, a different clinical
approach, particularly to the MRSA patients, could have
affected patients’ outcomes. Yet, the patient proﬁle reﬂected
in this study is not unique to our institution as resistant
pathogens are becoming more prevalent, particularly in elderly
patients with co-morbidities [26].
To conclude, both hVISA and MRSA IE cause devastating
disease with high mortality. Low rates of surgical intervention
and P/ICD extraction reﬂect the high co-morbidity of these
patients. The results underscore the importance of early
diagnosis of hVISA. Caution should be employed in the
empirical use of daptomycin due to the possibility of sponta-
neous resistance in hVISA isolates.
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